

XOMA LTD /DE/
Form 8-K
April 09, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 8, 2009

XOMA LTD.

(Exact name of registrant as specified in its charter)

BERMUDA

(State or other jurisdiction of incorporation)

0-14710

(Commission File Number)

2910 Seventh Street, Berkeley, California

(Address of principal executive offices)

52-2154066

(IRS Employer Identification No.)

94710

(Zip code)

Registrant's telephone number, including area code

(510) 204-7200

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On April 8, 2009, the U.S. Food and Drug Administration (the “FDA”) announced that Genentech, Inc. has begun a voluntary phased withdrawal of RAPTIVA® (efalizumab) from the United States market. The FDA Statement is attached as Exhibit 1 hereto and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

1. Statement issued by the FDA dated April 8, 2009
-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 8, 2009

XOMA LTD.
By: /s/ Christopher J.
Margolin
Christopher J. Margolin
Vice President, General Counsel and
Secretary

EXHIBIT INDEX

Number	Description
1.	Statement issued by the FDA dated April 8, 2009